Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Histological documentation of esophageal squamous cell carcinoma; * At least one measurable lesion (by RECIST1.1); * Patients who have failed to a chemoradiation treatment; * 18-75，ECOG PS:0-1,Life expectancy of more than 12 weeks; * No treated with molecular targeted drugs; * Main organs function is normal; * Patients should participate in the study voluntarily and sign informed consent; Exclusion Criteria: * Allergic to anlotinib and/or its excipients; * Patients with any severe and/or unable to control diseases，including： 1. Blood pressure unable to be controlled ideally(systolic pressure \>140 mmHg，diastolic pressure\>90 mmHg); 2. Patients with Grade 2 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥450ms for male， QT≥470ms for female) and patients with Grade 3 or higher congestive heart failure (NYHA Classification) or LVEF\<50%; * Patients with a clear Gastrointestinal bleeding tendency include the following situations: Local active ulcer lesions, and fecal occult blood (+ +) ; The patient had a history of black and hematemesis within 2 months; * Patients with a bleeding tendency and INR\>1.5,APTT\>1.5 ULN ; * Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.); * Patients with active brain metastasis, cancerous meningitis, spinal cord compression patients or found in Screening stage; * Patients treated with VEGFR inhibitor; * Patients with drug abuse history and unable to get rid of or Patients with mental disorders; * Patients participated in other anticancer drug clinical trials within 4 weeks; * Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment;